<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">13678730</PMID>
        <DateCompleted>
            <Year>2003</Year>
            <Month>10</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2019</Year>
            <Month>08</Month>
            <Day>27</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0090-8258</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>90</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Gynecologic oncology</Title>
                <ISOAbbreviation>Gynecol Oncol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>593-6</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">There is a need to find agents with activity in platinum and taxane refractory ovarian cancer to be employed as second-line therapy in the malignancy. Limited clinical trial experience has suggested that gemcitabine possesses activity in this clinical setting. We wished to further define the level of activity of gemcitabine in women with well-characterized platinum/taxane refractory disease.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Patients with ovarian or fallopian tube cancer or primary carcinoma of the peritoneum, whose disease had either failed to respond to a platinum and taxane treatment, or had responded but the &quot;treatment free interval (TFI)&quot; was &lt; or =3 months, or if the TFI was &gt;3 months and they had been retreated with the agents and not responded (or experienced a TFI of &lt;3 months), were eligible for treatment on this phase 2 single institution protocol. Gemcitabine was administered weekly (as a 1-h infusion) for 3 weeks, followed by 1-week break.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 51 patients were treated on this trial. The initial dose level (1250 mg/m(2)/week) resulted in excessive toxicity (fatigue, fever/chills, bone marrow suppression). The modified starting dose (1000 mg/m(2)/week) resulted in a more acceptable side effect profile. Eight patients (16%) with measurable disease (n = 4) or evaluable disease by CA-125 criteria (n = 4) achieved an objective response (median duration of response: 4 months; range 2-13 months).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Single agent gemcitabine possesses modest, but definite, activity in patients with well-characterized platinum/taxane resistant ovarian cancer. It is reasonable to consider this drug for second-line (or later) treatment in this clinical setting.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Markman</LastName>
                    <ForeName>Maurie</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Cleveland Clinic Taussig Cancer Center, Department of Gynecology/Obstetrics, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA. markman@ccf.org</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Webster</LastName>
                    <ForeName>Kenneth</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zanotti</LastName>
                    <ForeName>Kristine</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kulp</LastName>
                    <ForeName>Barbara</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Peterson</LastName>
                    <ForeName>Gertrude</ForeName>
                    <Initials>G</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Belinson</LastName>
                    <ForeName>Jerome</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Gynecol Oncol</MedlineTA>
            <NlmUniqueID>0365304</NlmUniqueID>
            <ISSNLinking>0090-8258</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000964">Antimetabolites, Antineoplastic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D009944">Organoplatinum Compounds</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0W860991D6</RegistryNumber>
                <NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>B76N6SBZ8R</RegistryNumber>
                <NameOfSubstance UI="C056507">gemcitabine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>P88XT4IS4D</RegistryNumber>
                <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000964" MajorTopicYN="N">Antimetabolites, Antineoplastic</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D003841" MajorTopicYN="N">Deoxycytidine</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018432" MajorTopicYN="N">Drug Resistance, Multiple</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005185" MajorTopicYN="N">Fallopian Tube Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009944" MajorTopicYN="N">Organoplatinum Compounds</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName>
                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName>
                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>9</Month>
                <Day>19</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2003</Year>
                <Month>10</Month>
                <Day>21</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>9</Month>
                <Day>19</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">13678730</ArticleId>
            <ArticleId IdType="pii">S0090825803003998</ArticleId>
            <ArticleId IdType="doi">10.1016/s0090-8258(03)00399-8</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
